

BIOPHEN Protein C (PC) technical file (#A221202/A221205)

Intended use and applications

IVD: ⊠ CE ⊠ 510(k) □ RUO

Diagnosis of congenital or acquired PC deficiencies (eg in dicumarol therapy, hepatic diseases, recurrent venous thromboses, or in DIC contexts).

Principle

- Quantitative determination of PC activity in human citrated plasma, using a chromogenic method, manual or automated.
- **R1:** Protac® (PC activator) lyophilised.
- **R2:** aPC specific chromogenic substrate (SaPC-21), lyophilised.

Characteristics and advantages

- Simple and rapid: ready to use after reconstitution; total assay time < 15 min.
- Easy to use on major coagulation analyzers, microplate or with basic equipment (~60-75 or 160-200 tests per kit (STARmicroplate).
- Associated calibrators and controls validated against the International Standard for PC (NIBSC).
- Dynamic range \sim 0 100% PC in human citrated plasma (dilution 1:2 with physiological saline)
- Detection threshold < 5%
- Highly specific, sensitive, reproducible (PC deficient plasma <5%; Intra assay CV 0.4-1.2 %; Inter assay CV 1.3-2.0 %)
- Highly stable (3 months at 2-8 C, 3 days at RT(18-25 C)).
- Safe, optimized, standardized: highly purified raw materials; inter lots correlation r2=0.95
- No significant interference of heparin<11U/ml, bilirubin<0.1mg/ml, haemoglobin<1mg/ml, triglycerides<1.25mg/ml added to plasma.

